Last Updated on March 27, 2024 by The Health Master
Pricing
In a significant move towards enhancing accessibility and affordability of healthcare, the Department of Pharmaceuticals (DoP) has set up a Committee dedicated to reforming the pricing framework for drugs and medical devices in the country.
This initiative aims not only to regulate prices but also to ensure a balance between availability and affordability, while fostering growth and innovation in the pharmaceutical sector.
Understanding the Committee’s Mandate
1. Introduction to the Committee
The Committee, spearheaded by Arunish Chawla, Secretary, DoP, comprises key stakeholders including Kamlesh Kumar Pant, Chairman of National Pharmaceutical Pricing Authority (NPPA), and Awadhesh Kumar Choudhary, Senior Economic Advisor, DoP.
Additionally, two representatives from the industry, one from the Indian Pharmaceutical Alliance (IP Alliance) and one from the Indian Drugs Manufacturers’ Association (IDMA), have been appointed as special invitees.
2. Objectives of the Committee
The primary objective of the Committee is to prepare a comprehensive draft Drugs and Medical Devices (Control) Order within a three-month timeline.
Key areas of focus include institutional reforms for the NPPA, designing a price moderation framework for medical devices, and ensuring timely access to emerging therapies for patients in need.
3. Key Considerations
The Committee will deliberate on several critical aspects, including:
- Balancing price and availability of essential medicines
- Providing incentives for industry growth and exports
- Designing a price moderation framework for medical devices to minimize imports
- Facilitating timely access to emerging and precision therapies
Historical Context and Legislative Framework
4. Evolution of Drug Pricing Policies
The journey of drug price regulation in India dates back to 1962 when the country witnessed a surge in medicine prices due to external factors like war.
Subsequent legislative measures, including the Drugs (Control of Prices) Order, 1963, aimed to freeze drug prices and introduce price control mechanisms.
5. Impact of Government Committees
Over the years, various government-appointed committees such as the Kelkar Committee, Pronab Sen Committee, and Sandhu Committee have influenced drug pricing policies.
These committees proposed recommendations ranging from exclusion of certain drugs from price control to the formulation of trade margin regulations.
6. National Pharmaceutical Pricing Policy (NPPP)
The introduction of the National Pharmaceutical Pricing Policy in 2012 marked a shift from cost-based pricing to market-based pricing, thereby aligning drug pricing regulations with market dynamics.
This policy laid the foundation for the Drug Price Control Order (DPCO), 2013, which further streamlined drug pricing mechanisms.
Current Challenges and Future Prospects
7. Addressing Healthcare Disparities
The Committee’s efforts towards reforming drug pricing hold immense significance in addressing healthcare disparities by ensuring equitable access to essential medicines and medical devices across socio-economic strata.
8. Promoting Innovation and Industry Growth
By providing a conducive environment for innovation and growth, the revamped pricing framework is poised to incentivize pharmaceutical companies to invest in research and development, ultimately leading to a more robust healthcare ecosystem.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
NPPA updated price lists: Download
Latest Notifications: EC Act (Essential Commodities Act)
FAQs – On DPCO: Drugs (Prices Control) Order, 2013
DCGI to SLAs: Cancel this Antibiotic Drug Combination
Need for a Unified Licensing and Drug Approval System in India
Govt Job: For Analyst at State Drugs Testing Laboratory
Operation Double-Check: Kerala’s Bold Move to Ensure Drug Quality
DTAB advocates Bar Codes and QR Codes on Vaccine Products
USFDA issued Form 483 with 4 observations to Alembic Pharma
Telangana: Illegal sale of drugs, 3 arrested under NDPS Act
A New Era for Pharma: Landmark Drug Testing Laboratory in Himachal Pradesh
Journey of OTC Drugs Regulation in India
Drug recall: Mesalamine capsules recalled Due to this reason
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: